Akebia shares decline after the company ends plans for its VALOR trial, citing FDA feedback and high costs tied to expanding ...
Analysis of the data from the open-label pivotal trial of oxylanthanum carbonate (OLC) highlights that pill burden was ...
Stocktwits on MSN
Akebia Therapeutics Stock Slumps After FDA Meeting Ends Without Path Forward for Vafseo Label Expansion
Vafseo is currently indicated for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months. ・The company said on Tuesday that it met ...
The results could help expand use of Welireg, one of the medicines Merck is counting on to drive revenue growth when its ...
Everyday Health on MSN
A Guide to Medications for Type 2 Diabetes and Chronic Kidney Disease
Learn about the current medication options for managing type 2 diabetes and chronic kidney disease, including SGLT2 inhibitors, GLP-1 receptor agonists, and more.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback